【摘要】 【关键词】 胸腺肽α1 阿德福韦酯 乙型肝炎 肝硬化 Clinical Analysis on Thymosinα1 and Adefovir Dipivoxil for the Treatment of Symptomatic Hepatitis B Cirrhosis Hu Xu-dong,Cheng Hai-lin,Cao Rong,et al. (Department of Gastroenterology,Wuhan Medical Treatment Center,Wuhan 430014,China) 【ABSTRACT】 Objective:To evaluate the efficacy and safety of Thymosinα1(Maipxin)and Adefovir Dipivoxil(ADV)in the treatment of symptomatic hepatitis B cirrhosis.Methods:80 symptomatic hepatitis B cirrhosis patients with HBVDNA and HBeAg positive are randomized into treatment group or control group.Both groups received ordinary liver protection and ADV while patients in treatment group took additional Maipxin.Results:After 52 weeks,the treatment group to improve hepatic function(TBIL,ALT,ALB)and PTA was superior to the control group(P<0.05),The effect of treatment group on decreasing HA,PCⅢ,LN and Ⅳ-C was more obvious than that of the control group(P<0.05).The clearance rates of HBV DNA in treatment group was 92.5%(37/40)and in control group was 70.0%(28/40),which had significant differences(P<0.01).The clearance rates of HBeAg in treatment group were 32.5%(13/40)and in control group were 12.5%(4/40),which had significant differences(P<0.05).The blood serum transformation rate in treatment group was 17.5%(7/40)and in control group was 5.0%(2/40),which had no significant differences(P>0.05).Conclusions:Treatment with Thymosinα1(Maipxin)and Adefovir Dipivoxil(ADV)on symptomatic hepatitis B cirrhosis significantly reduced serum HBV DNA levels,improved hepatic function and delayed the course of symptomatic hepatitis B cirrhosis.The patients tolerated well and no adverse effects were observed. 【KEY WORDS】Thymosinα1;Adefovir Dipivoxil;Hepatitis B;Liver cirrhosis 乙型肝炎病毒(HBV)持续感染是引起乙型肝炎慢性化及肝硬化的主要原因,乙型肝炎肝硬化患者HBV活跃复制与肝炎肝硬化的发生发展有关[1],因此,对活动性乙型肝炎肝硬化患者抗病毒治疗也应该是治疗的重要措施。阿德福韦酯是新型的核苷类抗乙型肝炎病毒药物,对HBV有很好的抑制作用[2]。胸腺肽α1(迈普新)具有使机体发挥免疫防护功能[3],因而可以达到抑制和清除病毒的效果,同时还有促进受损肝细胞的恢复。为此,我们应用胸腺肽α1联合阿德福韦酯治疗活动性乙型肝炎肝硬化,临床疗效满意,现报道如下。 1.2 方法 2.2 两组治疗后HBV-DNA、HBeAg阴转率及HBeAg/HBeAb血清转换的比较,见表2。 2.3 两组治疗后血清肝纤维化指标的变化,见表3。 表1 两组治疗前后肝功能及凝血功能的比较(略) 注:*与治疗后对照组相比较,P<0.05,差异有显著性 表2 两组治疗后HBV-DNA、HBeAg阴转率及HBeAg/HBeAb血清转换的比较(略) 注:*与对照组相比较,P>0.05,差异无显著性;#与对照组相比较,P<0.01,差异有极显著性 表3 两组治疗前后血清肝纤维化指标变化(略) 注:*与治疗后对照组相比较,差异有显著性,P<0.052.4 不良反应 观察过程中未见不良反应发生。 |
胸腺肽α1联合阿德福韦酯治疗活动性乙型肝炎肝硬化的临床观察简介:
【摘要】 目的:探讨胸腺肽α1(迈普新)联合阿德福韦酯治疗活动性乙型肝炎肝硬化的疗效和安全性。方法:选择HBeAg阳性的活动性乙型肝炎肝硬化80例随机分成治疗组和对照组,两组在综合保肝治疗基 ... 责任编辑:admin |
最新文章更多
推荐文章更多
热点文章更多 |